New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Brought to you by 
Acorda licenses Biogen Idec ex-US rights to Fampridine-SR
Jul 2009
Executive Summary
Acorda Therapeutics (developing therapies for nervous system disorders) has licensed Biogen Idec exclusive ex-US rights to develop and commercialize the multiple sclerosis drug Fampridine-SR and any aminopyridine therapeutics.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R+D and Marketing-Licensing
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acorda licenses Biogen Idec ex-US rights to Fampridine-SR
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice